IP Library Patent Application 14207220
Patent Application
App. No. 14/207,220

CELL REPOPULATED COLLAGEN MATRIX FOR SOFT TISSUE REPAIR AND REGENERATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/207,220
Abstract

The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.

Claims (36)

1 . A composition for treating a soft tissue injury in a subject, the composition comprising:

a collagen matrix, and

mesenchymal stem cells adhered to the collagen matrix, wherein the mesenchymal stem cells are derived from a tissue processed to form a cell suspension comprising mesenchymal stem cells and non-mesenchymal stem cells that is seeded onto the collagen matrix, and wherein the mesenchymal stem cells are not cultured ex vivo after formation of the cell suspension and prior to seeding of the cell suspension on the collagen matrix.

2 . The composition of claim 1 , wherein the collagen matrix is skin, dermis, tendon, ligament, muscle, amnion, meniscus, small intestine submucosa, or bladder.

3 . The composition of claim 1 , wherein the collagen matrix is treated to reduce immunogenicity.

4 - 6 . (canceled)

7 . The composition of claim 3 , wherein the treated collagen matrix retains bioactive cytokines.

8 . (canceled)

9 . The composition of claim 3 , wherein the treated collagen matrix retains bioactive growth factors.

10 . (canceled)

11 . The composition of claim 1 , wherein the collagen matrix is decellularized dermis.

12 . The composition of claim 1 , wherein the collagen matrix is dermis from which the epidermis layer has been removed.

13 . The composition of claim 1 , wherein the collagen matrix is human, porcine, bovine, or equine.

14 . The composition of claim 1 , wherein the tissue that is processed to form the cell suspension is selected from adipose tissue, muscle tissue, birth tissue, skin tissue, bone tissue, or bone marrow tissue.

15 - 20 . (canceled)

21 . The composition of claim 1 , wherein the mesenchymal stem cells seeded on the collagen matrix express one or more positive mesenchymal stem cell markers.

22 . (canceled)

23 . A method of treating a soft tissue injury in a subject, the method comprising contacting the composition of claim 1 to the site of the soft tissue injury.

24 . The method of claim 23 , wherein the soft tissue injury is an injury to a tendon tissue, a ligament tissue, a meniscus tissue, a muscle tissue, a skin tissue, a bladder tissue, or a dermal tissue.

25 - 30 . (canceled)

31 . A method of making a composition for treating a soft tissue injury, the method comprising:

(a) digesting a tissue to form a cell suspension comprising mesenchymal stem cells and non-mesenchymal stem cells;

(b) seeding the cell suspension onto a collagen matrix;

(c) incubating the collagen matrix seeded with the cell suspension under conditions suitable for adhering the mesenchymal stem cells to the collagen matrix; and

(d) removing the non-adherent cells from the collagen matrix.

32 . The method of claim 31 , wherein the collagen matrix is skin, dermis, tendon, ligament, muscle, amnion, meniscus, small intestine submucosa, or bladder.

33 . The method of claim 31 , wherein prior to step (b), the method further comprises treating the collagen matrix to reduce immunogenicity.

34 - 37 . (canceled)

38 . The method of claim 33 , wherein the treated collagen matrix is non-immunogenic.

39 . The method of claim 33 , wherein the treated collagen matrix retains bioactive cytokines.

40 . (canceled)

41 . The method of claim 33 , wherein the treated collagen matrix retains bioactive growth factors.

42 . (canceled)

43 . The method of claim 31 , wherein the collagen matrix is human, porcine, bovine, or equine.

44 . The method of claim 31 , wherein the tissue that is digested to form the cell suspension is selected from adipose tissue, muscle tissue, birth tissue, skin tissue, bone tissue, or bone marrow tissue.

45 - 51 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2014
From: SHI, YALING; DITTMAN, BRIAN; ATKINSON, BRENT; STILWELL, REGINALD L.
To: ALLOSOURCE
Reel/Frame 032703/0897 →